Sign In

Login

Password

Forgot Password ? Sign Up

アメナメビル (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "アメナメビル" in Japanese language version.

refsWebsite
Global rank Japanese rank
4nih.gov
4th place
24th place
2doi.org
2nd place
6th place
1evaluategroup.com
low place
low place

doi.org

  • Kawashima M, and others. (November 2017). “Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study”. The Journal of Dermatology 44 (11): 1219–1227. doi:10.1111/1346-8138.13948. PMC 5697646. PMID 28681394. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697646/6 
  • “Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor”. Antiviral Research 139: 95–101. (March 2017). doi:10.1016/j.antiviral.2016.12.008. PMID 280279176 

evaluategroup.com

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Kawashima M, and others. (November 2017). “Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study”. The Journal of Dermatology 44 (11): 1219–1227. doi:10.1111/1346-8138.13948. PMC 5697646. PMID 28681394. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697646/6 
  • “Profile of anti-herpetic action of ASP2151 (amenamevir) as a helicase-primase inhibitor”. Antiviral Research 139: 95–101. (March 2017). doi:10.1016/j.antiviral.2016.12.008. PMID 280279176 

ncbi.nlm.nih.gov

  • Kawashima M, and others. (November 2017). “Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study”. The Journal of Dermatology 44 (11): 1219–1227. doi:10.1111/1346-8138.13948. PMC 5697646. PMID 28681394. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697646/6 

pmc.ncbi.nlm.nih.gov

  • Kawashima M, and others. (November 2017). “Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study”. The Journal of Dermatology 44 (11): 1219–1227. doi:10.1111/1346-8138.13948. PMC 5697646. PMID 28681394. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5697646/6